CHO Plus Secures U.S. Patent for Enhanced Protein Production
CHO Plus Achieves Patent for Advanced Protein Production Techniques
In a significant advancement for biopharmaceutical manufacturing, CHO Plus, Inc. has received a U.S. Patent No. 12,404,502 from the United States Patent and Trademark Office. This patent centers around an innovative technology that enables the fusion of yeast cells to create hybrid cells, which dramatically increase the production of recombinant proteins. The process harnesses the power of these hybrid cells, known for their high levels of endoplasmic reticulum, essential for effective protein synthesis.
Broad Applications of Engineered Yeast in Various Industries
The implications of yeast technology span various industries. In the food sector, yeast serves as a vital component for producing alternative proteins, such as egg substitutes like ovalbumin and dairy alternatives like casein. Furthermore, yeast plays a critical role in pharmaceuticals, where it is instrumental in manufacturing therapeutic agents, including insulin and vaccines. Additionally, the industrial applications of yeast are impressive, extending to the production of silk, metal-binding proteins, enzymes like amylase, and fermentation processes.
Statements from CHO Plus Leadership
Larry Forman, the founder and CEO of CHO Plus, expressed excitement about the new patent, stating, "We continue to develop and expand our cell engineering technologies. This innovation is a game changer that can significantly boost productivity for essential food ingredients and various industrial products, thanks to engineered yeast cells." The enthusiasm surrounding this patent hints at a promising future for both food and pharmaceutical production.
Exceptional Results in Pharmaceutical Manufacturing
CHO Plus has recently demonstrated remarkable results in pharmaceutical manufacturing with their engineered cell lines. Engineered CHO cells yield up to ten times more therapeutic antibodies than their non-engineered counterparts, while engineered HEK-293 cells have shown the capability to produce twenty times more AAV vectors, with 55% of these achieving full capsid structures prior to purification. The company’s unwavering focus on innovation positions it as a leader in producing therapeutic proteins and gene therapy vectors, aiming to address numerous clinical challenges.
Looking Ahead: Collaboration and Partnerships
CHO Plus is continually drawing interest in its mammalian cell technologies, highlighting their CHO and HEK-293 cell lines. With the launch of this new patent, the company is eager to forge significant partnerships for funding and technology collaboration. Their objective is to advance the utilization of engineered yeast cells, both for food production and pharmaceutical applications.
About CHO Plus, Inc.
Founded with the goal of enhancing the productivity of cells utilized in the manufacture of life-saving therapeutic agents, CHO Plus, Inc. is a privately-held company. With a robust suite of technologies designed to create highly productive, good manufacturing practice (GMP)-compliant mammalian cell lines, they aim to manufacture therapeutic proteins and viral vectors for gene therapy. CHO Plus holds multiple patents, some granted and others pending, covering numerous technologies across various jurisdictions.
Contact Information
If you wish to learn more about CHO Plus or their innovative technologies, please reach out to:
Larry Forman, Founder and CEO, CHO Plus, Inc.
+1 (845) 380-6993
Email: Larry@CHO-Plus.com
Website: www.CHO-Plus.com
LinkedIn: CHO Plus on LinkedIn
Frequently Asked Questions
What is the new patent awarded to CHO Plus about?
The patent covers a technology for fusing yeast cells, creating hybrid cells that enhance protein production significantly.
How does this technology benefit the food industry?
It allows for the production of recombinant substitutes for egg and milk proteins, improving the availability of plant-based and alternative proteins.
What advancements has CHO Plus made in pharmaceutical applications?
CHO Plus's engineered cells demonstrate significant increases in the production of therapeutic antibodies and AAV vectors, marking a breakthrough in the sector.
What are the goals of CHO Plus moving forward?
CHO Plus aims to collaborate with major partners to expand the use of engineered yeast cells in food and pharmaceutical production.
How can I get in touch with CHO Plus?
You can contact Larry Forman at +1 (845) 380-6993 or via email at Larry@CHO-Plus.com for inquiries about their technologies.
About The Author
Contact Dominic Sanders privately here. Or send an email with ATTN: Dominic Sanders as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
